ReviewHealthcare (Basel, Switzerland)2018
Precision Medicine for Alzheimer's Disease Prevention.
Review in Healthcare (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- A Systematic Review on Predictors of Working Memory Training Responsiveness in Healthy Older Adults: Methodological Challenges and Future Directions.Frontiers in aging neuroscience · 2020Pooled it
- The gut-brain axis in Alzheimer's and Parkinson's diseases: a comparative perspective.Frontiers in microbiomes · 2026Review
- Article
- Cutting-edge Strategies for Overcoming Therapeutic Barriers in Alzheimer's Disease.Current pharmaceutical design · 2025Review
- Biomarker-Based Precision Therapy for Alzheimer's Disease: Multidimensional Evidence Leading a New Breakthrough in Personalized Medicine.Journal of clinical medicine · 2024Review
- A Comprehensive Review of Modifiable Cardiovascular Risk Factors and Genetic Influences in Dementia Prevention.Cureus · 2023Review
- Aducanumab-Hope or Disappointment for Alzheimer's Disease.International journal of molecular sciences · 2023Review
- The Future of Precision Medicine in the Cure of Alzheimer's Disease.Biomedicines · 2023Review
- Precision Medicine Approach to Alzheimer's Disease: Rationale and Implications.Journal of Alzheimer's disease : JAD · 2023Review
- Extracellular vesicles and Alzheimer's disease in the novel era of Precision Medicine: implications for disease progression, diagnosis and treatment.Experimental neurology · 2022Review
- Alzheimer's Disease Prevention Health Coaching.The journal of prevention of Alzheimer's disease · 2022Article
- Cross-Cultural Adaptation and Validation of a French Version of the Genetic Counseling Satisfaction Scale (GCSS) as an Outcome Measure of Genetic Counseling for Hereditary Breast and Ovarian Cancer.Healthcare (Basel, Switzerland) · 2021Article
- Preventative medicine and Alzheimer's disease: is Alzheimer's disease risk reduction achievable?Neural regeneration research · 2021Article
- Exploring Alzheimer's Disease Molecular Variability via Calculation of Personalized Transcriptional Signatures.Biomolecules · 2020Article
- Addressing Alzheimer's Disease (AD) Neuropathology Using Anti-microRNA (AM) Strategies.Molecular neurobiology · 2019Review
- Physical Exercise as Personalized Medicine for Dementia Prevention?Frontiers in physiology · 2019Article
- Exploring precision medicine by utilizing individual genetic information for the management of Alzheimer's disease.PharmacogenomicsReview
- Protocol for the Asian Cohort for Alzheimer's Disease (ACAD) Study.Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precision medicine is an approach to medical treatment and prevention that takes into account individual variability in genes, environment, and lifestyle and allows for personalization that is based on factors that may affect the response to treatment. Several genetic and epigenetic risk factors have been shown to increase susceptibility to late-onset Alzheimer's disease (AD). As such, it may be beneficial to integrate genetic risk factors into the AD prevention approach, which in the past has primarily been focused on universal risk-reduction strategies for the general population rather than individualized interventions in a targeted fashion. This review discusses examples of a "one-size-fits-all" versus clinical precision medicine AD prevention strategy, in which the precision medicine approach considers two genes that can be commercially sequenced for polymorphisms associated with AD, apolipoprotein E (APOE), and methylenetetrahydrofolate reductase (MTHFR). Comparing these two distinct approaches provides support for a clinical precision medicine prevention strategy, which may ultimately lead to more favorable patient outcomes as the interventions are targeted to address individualized risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.